COMP <GO>
CTOR vs BOLD // REVENUE GROWTH (YOY)
Citius Oncology Inc. (NASDAQ) VS. Boundless Bio Inc. (NASDAQ) • 15-METRIC TALLY: CTOR 0
— BOLD 3
■ METRIC PARITY
LAST: $0.55 (-7.42%) • MKT CAP: $55.2M
revenue-growth
—
LAST: $2.38 (-2.46%) • MKT CAP: $56.4M
revenue-growth
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CTOR VS. BOLD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CTOR | BOLD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -11.16% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 3/9 | -2.00 | BOLD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.1 | 43.9 | -6.80 | BOLD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $55.2M | $56.4M | -$1.1M | BOLD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CTOR REV | BOLD REV | CTOR GROSS % | BOLD GROSS % | CTOR FCF | BOLD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $65.9M | $177.9M | — | — | -$5.5M | -$47.2M |
| FY 2024 | $57.6M | $205.1M | — | — | $126.4K | -$63.4M |
| FY 2023 | $2.8M | $153.4M | — | — | -$601.3K | -$46.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CTOR // BETA —
BOLD // BETA —